Retirement Systems of Alabama raised its position in ABIOMED, Inc. (NASDAQ:ABMD) by 0.3% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 75,635 shares of the medical equipment provider’s stock after buying an additional 261 shares during the period. Retirement Systems of Alabama’s holdings in ABIOMED were worth $10,838,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of ABMD. Northwestern Mutual Investment Management Company LLC boosted its position in ABIOMED by 0.4% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 6,978 shares of the medical equipment provider’s stock worth $874,000 after buying an additional 25 shares during the last quarter. Capstone Asset Management Co. boosted its position in ABIOMED by 1.1% in the second quarter. Capstone Asset Management Co. now owns 6,410 shares of the medical equipment provider’s stock worth $919,000 after buying an additional 70 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in ABIOMED by 1.2% in the first quarter. PNC Financial Services Group Inc. now owns 7,842 shares of the medical equipment provider’s stock worth $982,000 after buying an additional 95 shares during the last quarter. Texan Capital Management boosted its position in ABIOMED by 0.9% in the second quarter. Texan Capital Management now owns 11,779 shares of the medical equipment provider’s stock worth $1,688,000 after buying an additional 100 shares during the last quarter. Finally, World Asset Management Inc boosted its position in ABIOMED by 4.3% in the second quarter. World Asset Management Inc now owns 2,966 shares of the medical equipment provider’s stock worth $425,000 after buying an additional 122 shares during the last quarter. Institutional investors own 90.51% of the company’s stock.

ABIOMED, Inc. (NASDAQ ABMD) opened at 150.01 on Friday. The company’s 50 day moving average is $145.34 and its 200 day moving average is $130.46. The stock has a market cap of $6.58 billion, a PE ratio of 87.73 and a beta of 0.20. ABIOMED, Inc. has a 12 month low of $95.14 and a 12 month high of $157.41.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.03. The firm had revenue of $132.47 million during the quarter, compared to analyst estimates of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The business’s revenue was up 28.6% on a year-over-year basis. During the same quarter last year, the business earned $0.29 EPS. On average, analysts anticipate that ABIOMED, Inc. will post $2.24 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Retirement Systems of Alabama Has $10.84 Million Stake in ABIOMED, Inc. (ABMD)” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/retirement-systems-of-alabama-has-10-84-million-stake-in-abiomed-inc-abmd/1472935.html.

A number of research firms have issued reports on ABMD. BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Monday. Jefferies Group LLC boosted their price objective on shares of ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Piper Jaffray Companies restated an “overweight” rating and issued a $160.00 price objective (up previously from $145.00) on shares of ABIOMED in a research report on Thursday, July 27th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $140.00 price objective (up previously from $135.00) on shares of ABIOMED in a research report on Monday, July 10th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $158.29.

In related news, COO David M. Weber sold 16,500 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $147.63, for a total value of $2,435,895.00. Following the transaction, the chief operating officer now owns 125,122 shares of the company’s stock, valued at approximately $18,471,760.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Michael G. Howley sold 18,279 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $133.56, for a total transaction of $2,441,343.24. Following the completion of the transaction, the vice president now directly owns 62,105 shares in the company, valued at approximately $8,294,743.80. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.